Shanghai Shengdi Pharmaceutical Co., Ltd

This study tests whether adding the drug adebrelimab to standard chemoradiotherapy helps people with locally advanced cervical cancer live longer without their cancer growing. About 720 participants will receive either adebrelimab or a placebo alongside their usual treatment. The…

This study tests a new drug called SHR-4610 in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two parts: first, finding the safest dose, then checking if it shrinks tumors or slows their growth. About 258 adults aged 18-75 wit…

This study tests a new contrast agent called HRS-9231 for MRI scans of the brain and spine. About 250 adults with known or suspected brain or spine lesions will receive both HRS-9231 and a standard contrast agent (gadobutrol) in random order. The goal is to see if HRS-9231 is as …